2020
DOI: 10.1007/s12015-020-10061-2
|View full text |Cite
|
Sign up to set email alerts
|

A Concise Review on Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Personalized Regenerative Medicine

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
11
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 19 publications
(11 citation statements)
references
References 305 publications
0
11
0
Order By: Relevance
“…PSCs are primarily embryonic stem cells (ESCs) that are derived from an inner-cell mass of the preimplanted blastocyst or from primordial germ cells of the early embryos, and induced pluripotent stem cells (iPSCs) that are derived from somatic cells by using reprogramming factors and resemble ESCs in many ways. Although use of these cells faces ethical and safety concerns [ 8 ], they are widely studied for their superior differentiation potential over that of adult stem cells, and can hopefully be used for various therapeutic purposes in regenerative medicine in the future [ 9 ]. However, as early work tried to obtain cardiomyocytes from PSCs via different methods, such as the use of exogenous cytokines, growth factors, and extracellular matrix [ 10 ], these pluripotent stem cell-derived cardiomyocytes (PSC-CMs) turned out to be significantly more immature compared to adult cardiomyocytes and exhibit a fetal-like phenotype [ 11 ].…”
Section: Introductionmentioning
confidence: 99%
“…PSCs are primarily embryonic stem cells (ESCs) that are derived from an inner-cell mass of the preimplanted blastocyst or from primordial germ cells of the early embryos, and induced pluripotent stem cells (iPSCs) that are derived from somatic cells by using reprogramming factors and resemble ESCs in many ways. Although use of these cells faces ethical and safety concerns [ 8 ], they are widely studied for their superior differentiation potential over that of adult stem cells, and can hopefully be used for various therapeutic purposes in regenerative medicine in the future [ 9 ]. However, as early work tried to obtain cardiomyocytes from PSCs via different methods, such as the use of exogenous cytokines, growth factors, and extracellular matrix [ 10 ], these pluripotent stem cell-derived cardiomyocytes (PSC-CMs) turned out to be significantly more immature compared to adult cardiomyocytes and exhibit a fetal-like phenotype [ 11 ].…”
Section: Introductionmentioning
confidence: 99%
“…Mouse and human fibroblasts can be successfully converted into iPSCs by the overexpression of pluripotencyrelated transcription factors Oct4, Sox2, Klf4, and c-Myc [139,140] (Figure 3a). As iPSCs are generated from cells derived from patients' own body, iPSCs-derived cardiomyocytes (iPSCs-CM) are less prone to immune rejection, and there are no ethical concerns involved [141]. Under in vitro conditions, iPSCs can be pushed towards a cardiac fate the same way as ESCs, either through the formation of embryoid bodies or monolayer culture [141].…”
Section: Delivery Of De Novo Cardiomyocytes From Differentiated Escs/...mentioning
confidence: 99%
“…As iPSCs are generated from cells derived from patients' own body, iPSCs-derived cardiomyocytes (iPSCs-CM) are less prone to immune rejection, and there are no ethical concerns involved [141]. Under in vitro conditions, iPSCs can be pushed towards a cardiac fate the same way as ESCs, either through the formation of embryoid bodies or monolayer culture [141]. The use of small molecules has also been extensively exploited to increase the efficiency of cardiac differentiation.…”
Section: Delivery Of De Novo Cardiomyocytes From Differentiated Escs/...mentioning
confidence: 99%
“…As a result, a question about the experimental efficiency of iPSCs arises. Malignancies and oncogenes can also be induced in the host when employing viral vectors [23,30]. Maza et al found that lowering the Mbd3 gene can enable all cells to acquire pluripotency, which is a key hurdle to employing iPSCs in clinical practice [31].…”
Section: B Induced Pluripotent Stem Cells (Ipscs)mentioning
confidence: 99%